Clinical Trial

A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated February 25, 2016 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Whether patients with stage III clear cell renal cell carcinoma(ccRCC) should receive adjuvant targeted therapy or not is still on debate. The investigators invented a assay consisting of 5 CpGs: cg00396667（PITX1）, cg18815943 （FOXE3）, cg03890877（TWF2）, cg07611000 （EHBP1L1）and cg14391855（RIN1）that was successfully categorise patients with stage III clear cell renal cell carcinoma into high-risk and low-risk groups with Harzard Ratio(HR) of 4.93. Here the investigators randomly assign assay-defined high risk patients of locally advanced ccRCC into adjuvant targeted therapy group and observation group.Disease free survival and overall survival are the end points of observation.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT02688491
Lead Sponsor First Affiliated Hospital, Sun Yat-Sen University
Collaborators: Xi'an Jiaotong University, Yantai Yuhuangding Hospital, Sun Yat-sen University
Conditions Renal Neoplasms, Targeted Molecular Therapy
Enrollment 300 participants
Start Date 2016-07
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2016-02-25